首页 › 基金 › JACOBS LEVY EQUITY MANAGEMENT, INC › REGN
JACOBS LEVY EQUITY MANAGEMENT, INC 对 REGN 的持仓历史
REGENERON PHARMACEUTICALS · 医疗保健
JACOBS LEVY EQUITY MANAGEMENT, INC 在 Q2 2026 的 13F 申报中披露持有 REGN(REGENERON PHARMACEUTICALS)256,503 股,市值约 US$159.9M,约占其申报组合的 0.58%,在其申报持仓中市值排名第 36 位。 JACOBS LEVY EQUITY MANAGEMENT, INC 最近 11 个申报季度中有 11 个季度披露了 REGN 持仓,最早可追溯至 Q4 2023。
最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR
JACOBS LEVY EQUITY MANAGEMENT, INC 对 REGN 的持仓演变
JACOBS LEVY EQUITY MANAGEMENT, INC 于 Q4 2023 首次披露 REGN 持仓:356 股(约 US$313K)。 该持仓在 Q4 2025 达到峰值 264,991 股,市值约 US$204.5M。 在 11 次申报中,JACOBS LEVY EQUITY MANAGEMENT, INC 6 次增持、4 次减持、0 次保持不变。 最近一期申报(Q2 2026)显示持股 256,503 股、市值约 US$159.9M,环比增持 42,343 股。。 持仓曾出现大幅变动:Q2 2024 增持约 3596% (随后一个季度股价基本持平)、Q4 2024 减持约 96% (随后一个季度股价下跌 11%)、Q2 2025 增持约 31261% (随后一个季度股价上涨 8%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2023 | 356 | $312.67K | 新进 |
| Q1 2024 | 362 | $348.42K | 增持 |
| Q2 2024 | 13.38K | $14.06M | 增持 |
| Q3 2024 | 23.59K | $24.80M | 增持 |
| Q4 2024 | 847 | $603.34K | 减持 |
| Q1 2025 | 747 | $473.77K | 减持 |
| Q2 2025 | 234.27K | $122.99M | 增持 |
| Q3 2025 | 287.88K | $161.87M | 增持 |
| Q4 2025 | 264.99K | $204.54M | 减持 |
| Q1 2026 | 214.16K | $165.47M | 减持 |
| Q2 2026 | 256.50K | $159.94M | 增持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 REGN 与 13F 数据
REGN(REGENERON PHARMACEUTICALS)属于医疗保健行业。我们追踪的基金中还有 31 只申报持有 REGN,申报仓位最大的包括:Dodge & Cox (US$3.04B), DODGE & COX (US$3.04B), LOOMIS SAYLES & CO L P (US$1.16B)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 REGN 的基金
- Dodge & Cox 4.87M 股 · $3.04B · Q2 2026
- DODGE & COX 4.87M 股 · $3.04B · Q2 2026
- LOOMIS SAYLES & CO L P 1.86M 股 · $1.16B · Q2 2026
更多关于 JACOBS LEVY EQUITY MANAGEMENT, INC
常见问题
How long has JACOBS LEVY EQUITY MANAGEMENT, INC held REGN?
JACOBS LEVY EQUITY MANAGEMENT, INC has disclosed REGN holdings in 11 of the last 11 reported quarters, going back to Q4 2023.
What is JACOBS LEVY EQUITY MANAGEMENT, INC's current position in REGN?
As of Q2 2026, JACOBS LEVY EQUITY MANAGEMENT, INC holds 256.50K shares of REGN (REGENERON PHARMACEUTICALS), valued at $159.94M, representing 0.58% of its reported portfolio and ranking #36.
Has JACOBS LEVY EQUITY MANAGEMENT, INC been buying or selling REGN?
In the latest 13F filing (Q2 2026), JACOBS LEVY EQUITY MANAGEMENT, INC increased its position in REGN. The position peaked in Q4 2025 at 264.99K shares.
Which other funds hold REGN?
Other major institutional holders of REGN include Dodge & Cox, DODGE & COX, LOOMIS SAYLES & CO L P, among 31 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.